ACMS #29, March 2020

The 29th meeting of the Advisory Committee on Medicines Scheduling (ACMS #29), March 2020.

Date

11 March 2020

A meeting of the Advisory Committee on Medicines Scheduling (ACMS).

Members

The committee members are professionals with specific scientific, medical or clinical expertise, or expertise in consumer health issues relating to medicines.

Pre-meeting notice

For the pre-meeting public consultation notice go to:

Consultation: Proposed amendments to the Poisons Standard - ACCS, ACMS and Joint ACMS/ACCS meetings, March 2020.

Outcomes

Public submissions on melatonin, referred to the ACMS #29

28 September 2020

Scheduling submissions

Public submissions on matters referred to the March 2020 scheduling meetings, and received during the interim consultation period - melatonin
Notice of final decision to amend the current Poisons Standard in relation to melatonin

28 September 2020

Scheduling decisions (final)

Public notice of the Delegates' final decisions to amend (or not amend) the current Poisons Standard in relation to melatonin.
Public submissions on scheduling matters referred to the ACMS #29, ACCS #27 and Joint ACMS-ACCS #24 meetings held in March 2020

11 September 2020

Scheduling submissions

Public submissions on matters referred to the March 2020 scheduling meetings, and received during the interim consultation period

Topics

Meeting of

Advisory Committee on Medicines Scheduling (ACMS)

Sub menu

ACMS #29, March 2020

Members

Pre-meeting notice

Outcomes

Public submissions on melatonin, referred to the ACMS #29

Notice of final decision to amend the current Poisons Standard in relation to melatonin

Public submissions on scheduling matters referred to the ACMS #29, ACCS #27 and Joint ACMS-ACCS #24 meetings held in March 2020

Related content

Medical Devices – Essential Principles for Safety and Performance - Part 2 Proposed alignment with the European Regulations

Software reclassification reforms webinar: Q and A on the software transition deadline on 1 November 2024

GMP Forum 2024

Help us improve the Therapeutic Goods Administration site